Alliance Pharma PLC (LON:APH) has confirmed its morning sickness treatment Xonvea has received marketing approval in Ireland.
This paves the way for the first launch of the product outside the UK. The company to start selling the drug in the Republic in the final quarter of this year.
As in the UK, it will be prescribed for nausea and vomiting in pregnancy where conservative management has failed.
The condition affects 70-80% of women during pregnancy in Ireland, mirroring what is seen in Britain.